Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia
| Autoři | |
|---|---|
| Rok publikování | 2002 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Medical Science Monitor (International Medical Journal of Experimental and Clinical Research) |
| Fakulta / Pracoviště MU | |
| Citace | |
| Obor | Kardiovaskulární nemoci včetně kardiochirurgie |
| Klíčová slova | gene; endothelin; polymorphism; ET-1; arrhythmia; defibrillator |
| Popis | The endothelins are peptides with vasoconstriction and growth-promoting properties. Endothelin-1 (ET-1) is known for its direct positive inotropic and chronotropic effects on isolated heart, and for growth effects. The aim of this pilot study was to investigate the frequency distribution of a common polymorphism of the endothelin gene and its possible relation to the hemodynamic consequences of malignant ventricular arrhythmia in patients with structural heart disease. We studied 26 consecutive patients with malignant ventricular arrhythmia and implantable cardioverter defibrillators (ICD), mean age 62.7 years, mean LVEF 0.37. The Taq polymorphism of ET-1 was detected using our original PCR method. Out of the 26 patients, 9 (34%) had reccurent palpitations and 8 (30.8%) had syncopes during their malignant arrhythmic episodes. 19 of the patients were receiving amiodarone after ICD implantation, 7 were not. 15 patients had the (++) and 11 had (+-) ET-1 genotype, none had the (--) genotype. The risk of syncopes was associated with the (++) genotype (p=0.01). Patients with amiodarone had a significantly higher frequency of the (++) genotype (p=0.011). All our results suggested that the presence of the (++) ET-1 genotype in patients with structural heart disease, severe left ventricular dysfunction, and malignant ventricular arrhythmia put these patients at a higher risk of hemodynamic collapse during arrhythmic episodes. |
| Související projekty: |